(Q37039074)

17 August 2017

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia (English)

1 reference

17 August 2017

0 references

1 reference

1 reference

1 reference

1

Hagop Kantarjian

1 reference

17 August 2017

11

Stefan Faderl

1 reference

17 August 2017

12

Jorge Cortes

1 reference

17 August 2017

14

Susan O'Brien

1 reference

17 August 2017

8

Farhad Ravandi

1 reference

17 August 2017

5

Elias Jabbour

1 reference

17 August 2017

9

Rebecca Garris

1 reference

17 August 2017

3

Jeffrey Jorgensen

1 reference

17 August 2017

13

Richard Champlin

1 reference

17 August 2017

4

Partow Kebriaei

1 reference

17 August 2017

6

Michael Rytting

1 reference

17 August 2017

10

Monica Kwari

1 reference

17 August 2017

7

Sergernne York

1 reference

17 August 2017

Deborah Thomas

2

1 reference

PMC publication ID

3720844

17 August 2017

language of work or name

English

0 references

publication date

30 April 2013

1 reference

17 August 2017

1 reference

17 August 2017

119

1 reference

17 August 2017

15

1 reference

17 August 2017

2728-2736

1 reference

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Modern therapy of acute lymphoblastic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Adult acute lymphoblastic leukemia: concepts and strategies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Management of acute lymphoblastic leukemia in older patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720844

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23633004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.28136

1 reference

17 August 2017

1 reference

PMC publication ID

3720844

17 August 2017

PubMed publication ID

23633004

1 reference

PMC publication ID

3720844